Advances in serous tubal intraepithelial carcinoma: Correlation with high grade serous carcinoma and ovarian carcinogenesis

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 3, 2014, Pages 848-857

  Li, Hong Xia ^a,b   Lu, Zhao Hui ^b,c   Shen, Keng ^c   Cheng, Wen Jun ^a   Malpica, Anais ^b   Zhang, Jing ^e   Wei, Jian Jun ^d   Zhang, Zhi Hong ^a   Liu, Jinsong ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d NORTHWESTERN UNIVERSITY   (United States)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carcinogenesis; Fallopian tube; High grade serous carcinoma; Ovarian cancer; Serous tubal intraepithelial carcinoma

Indexed keywords

CARCINOMA IN SITU; CYSTADENOCARCINOMA; FEMALE; HUMAN; PATHOLOGY; UTERINE TUBE TUMOR;

CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS;

EID: 84899575209     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Tang S, Onuma K, Deb P, Wang E, Lytwyn A, Sur M and Daya D. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol 2012; 31: 103-110.
2. Colgan TJ, Murphy J, Cole DE, Narod S and Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25: 1283-1289.
3. Leeper K, Garcia R, Swisher E, Goff B, Greer B and Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002; 87: 52-56.
4. Finch A, Shaw P, Rosen B, Murphy J, Narod SA and Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100: 58-64.
5. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M and Ziegler J. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005; 23: 127-132.
6. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES and Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008; 53: 127-138.
7. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW and Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.
8. Shaw PA, Rouzbahman M, Pizer ES, Pintilie M and Begley H. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009; 22: 1133-1138.
9. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS and Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007; 25: 3985-3990.
10. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M and Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34: 1407-1416.
11. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ and Shih Ie M. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29: 218-224.
12. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
13. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG and Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-169.
14. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18 Suppl 2: S19-32.
15. Dalrymple JC, Bannatyne P, Russell P, Solomon HJ, Tattersall MH, Atkinson K, Carter J, Duval P, Elliott P, Friedlander M, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64: 110-115.
16. Bell DA and Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994; 73: 1859-1864.
17. Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am 1978; 58: 121-129.
18. Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K and Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000; 89: 383-390.
19. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL and Shih Ie M. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226: 421-426.
20. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD and Crum CP. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
21. Sehdev AS, Kurman RJ, Kuhn E and Shih Ie M. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol 2010; 23: 844-855.
22. Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ and Shih Ie M. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010; 34: 829-836.
23. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM and Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A 2012; 109: 3921-3926.
24. Nagaraja AK, Andreu-Vieyra C, Franco HL, Ma L, Chen R, Han DY, Zhu H, Agno JE, Gunaratne PH, DeMayo FJ and Matzuk MM. Deletion of Dicer in somatic cells of the female reproductive tract causes sterility. Mol Endocrinol 2008; 22: 2336-2352.
25. Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ and Richards JS. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 2009; 69: 6463-6472.
26. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y and Crum CP. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008; 27: 1-9.
27. Mahe E, Tang S, Deb P, Sur M, Lytwyn A and Daya D. Do deeper sections increase the fre quency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol? Int J Gynecol Pathol 2013; 32: 353-357.
28. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W and Crum CP. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol 2010; 222: 110-116.
29. Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH and van Diest PJ. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol 2013; 37: 1123-1130.
30. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R and Pasini B. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004; 23: 35-40.
31. Leunen K, Legius E, Moerman P, Amant F, Neven P and Vergote I. Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer 2006; 16: 183-188.
32. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P and Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456.
33. Carlson JW, Jarboe EA, Kindelberger D, Nucci MR, Hirsch MS and Crum CP. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol 2010; 29: 310-314.
34. Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, Shih Ie M and Kurman RJ. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol 2011; 35: 1766-1775.
35. Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Li RF, Ronnett BM, Seidman JD, Yemelyanova A, Shih Ie M, Shaw PA, Soslow RA and Kurman RJ. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012; 31: 243-253.
36. Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
37. Goh AM, Coffill CR and Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
38. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
39. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D and Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221: 49-56.
40. Levanon K, Crum C and Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-5293.
41. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010; 10: 803-808.
42. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M and Kurman RJ. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011; 24: 1248-1253.
43. DiCioccio RA, Werness BA, Peng R, Allen HJ and Piver MS. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet 1998; 105: 93-102.
44. Kobel M, Reuss A, Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG and Gilks CB. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010; 222: 191-198.
45. Engbring JA and Kleinman HK. The basement membrane matrix in malignancy. J Pathol 2003; 200: 465-470.
46. Gritsenko PG, Ilina O and Friedl P. Interstitial guidance of cancer invasion. J Pathol 2012; 226: 185-199.
47. Scheele S, Nystrom A, Durbeej M, Talts JF, Ekblom M and Ekblom P. Laminin isoforms in development and disease. J Mol Med (Berl) 2007; 85: 825-836.
48. Patarroyo M, Tryggvason K and Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 2002; 12: 197-207.
49. Kuhn E, Kurman RJ, Soslow RA, Han G, Sehdev AS, Morin PJ, Wang TL and Shih Ie M. The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol 2012; 36: 1826-1834.
50. Barth TF, Rinaldi N, Bruderlein S, Mechtersheimer G, Strater J, Altevogt P and Moller P. Mesothelial cells in suspension expose an enriched integrin repertoire capable of capturing soluble fibronectin and laminin. Cell Commun Adhes 2002; 9: 1-14.
51. Saito Y, Sekine W, Sano R, Komatsu S, Mizuno H, Katabami K, Shimada K, Oku T and Tsuji T. Potentiation of cell invasion and matrix metalloproteinase production by alpha3beta1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clin Exp Metastasis 2010; 27: 197-205.
52. Witz CA, Takahashi A, Montoya-Rodriguez IA, Cho S and Schenken RS. Expression of the alpha2beta1 and alpha3beta1 integrins at the surface of mesothelial cells: a potential attachment site of endometrial cells. Fertil Steril 2000; 74: 579-584.
53. Cleynen I and Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008; 32: 289-305.
54. Reeves R. Structure and function of the HMGI(Y) family of architectural transcription factors. Environ Health Perspect 2000; 108 Suppl 5: 803-809.
55. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schafer R and Tchernitsa O. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008; 123: 348-356.
56. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E and Peter ME. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007; 6: 2585-2590.
57. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA and Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001; 98: 1176-1181.
58. Gattas GJ, Quade BJ, Nowak RA and Morton CC. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 1999; 25: 316-322.
59. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U and Bullerdiek J. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996; 149: 775-779.
60. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P and Wei JJ. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008; 6: 663-673.
61. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E and Peter ME. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007; 104: 11400-11405.
62. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A and Resar LM. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 2009; 22: 43-49.
63. Fusco A and Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7: 899-910.
64. Hebert C, Norris K, Scheper MA, Nikitakis N and Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007; 6: 5.
65. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y and Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009; 174: 854-868.
66. Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P and Liu J. HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 2010; 34: 18-26.
67. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG and Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006; 13: 1-7.
68. Jarboe EA, Miron A, Carlson JW, Hirsch MS, Kindelberger D, Mutter GL, Crum CP and Nucci MR. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol 2009; 28: 308-315.
69. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G and Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 2013; 495: 241-245.